2 Information about abemaciclib with fulvestrant

Marketing authorisation indication

2.1 Abemaciclib (Verzenios, Eli Lilly) is indicated 'for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine‑based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price for abemaciclib is £2,950 per 28 day cycle (excluding VAT; BNF online, accessed January 2021):

  • for 150 mg tablets: £1,475 per 28 tablet pack or £2,950 per 56 tablet pack

  • for 100 mg tablets: £1,475 per 28 tablet pack or £2,950 per 56 tablet pack

  • for 50 mg tablets: £1,475 per 28 tablet pack or £2,950 per 56 tablet pack of 50 mg tablets.

2.4 The list price for fulvestrant is £522.41 for two 250 mg/5 ml prefilled syringes of solution for injection (excluding VAT; BNF online, accessed January 2021). This equates to £1,044.82 for the first cycle, and £522.41 for subsequent cycles.

2.5 The company has a commercial arrangement. This makes abemaciclib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)